August 1, 2013
Bookmark and Share  




Last week was World Hepatitis Day and President Obama declared World Hepatitis Day in the U.S.  We have come a long way, but we still have a long way to go before everyone with HCV is tested and has access to medical care and treatment.  But the recent advocacy accomplishments are very inspiring!     

In this week’s E-blast we have many interesting and important articles





1. HCV Advocate Newsletter: August, 2013

In This Issue:

  • USPSTF: Test All Baby Boomers & At-Risk Adults!
    Alan Franciscus, Editor-in-Chief —This was one big accomplishment for the HCV advocacy community and everyone should be inspired about what we can accomplish by working together. We have also updated our Baby Boomer postcard and we are offering free postcards to disseminate.

  • Snapshots
    Lucinda K. Porter, RN—Read about B-cell non-Hogkins lymphoma and HCV, skin reactions from telaprevir-based therapy, predicting treatment success, and barriers to HCV treatment.

  • HEALTHWISE: When A and E Meet Hepatitis C
    Lucinda K. Porter, RN
    —Read about the 'other' hepatitis viruses and how to prevent them.

  • DISABILITY & BENEFITS: Medicaid & the Affordable Care Act (ACA)
    Jacques Chambers, CLU—In this month's column, Jacques discusses ACA and Medicaid and what to expect.


2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B:

  • First Clinical Trial Using “RNA Interference” for Hepatitis B Begins
  • Why Do Some People Clear HBsAg After Years of Chronic Infection?
  • Longer Antiviral Treatment Urged after Seroconversion to Prevent Relapse
  • Federal Officials Dramatically Undercount Liver Disease Deaths in the U.S.
  • More Women Than Men Retain Protection Against Hepatitis B After Immunization
  • Hepatitis B Cirrhosis Declines in China, But Alcohol-related Cirrhosis Rises
  • Hepatitis E Vaccine Development Shows Promise
  • Tenofovir Most Effective Antiviral Treatment in HIV-HBV Coinfected Patients
  • Study Confirms Coffee Protects the Liver in European Populations
  • Hepatitis C Is Also a Risk for Southeast Asians, Including Women
  • In Small Trial, Chinese Herbal Medicine Reduces ALT Levels


3. Factsheets & Guides: New & Updated!

Be sure to check out our recently updated fact sheets and guides:

HIV/HCV Coinfection Basics Series

HIV/HCV Coinfection Facts Series

HIV/HCV Coinfection: HCV Treatment
Click Here


4. Updated HCV Training Workshop Schedule!

  • September

    Livingston, NJ—September 23, 2013—Click Here

    Oklahoma, OK—September 25, 2013—Click Here

    Tulsa, OK—September 26, 2013—Click Here


5. Clinical Trials Postings: Updated—July 3!
Be sure to check out the latest clinical trial postings at the HCV Advocate News & Pipeline Blog. Just click on the links to the Drug Companies at the top and to see which drugs are in trials right now, where the trials are, and how to register for one.



Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time.  For more information about the services they offer either call or visit their Website at  The helpline is run by The Support Partnership:  a group of non-profits working together to help people affected by hepatitis C. 


6. Top News (Blog) from the HCV Advocate News & Pipeline Blog includes: 

Top News

Engineered mice act as hepatitis C model
July 31

"C" This Is What It Is Concert: August 31, 2013
July 31

White House Hosts U.S. Observance of World Hepatitis Day
July 31

Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C
July 31

To End Hepatitis C, Patients Must Come Before Profits
July 30

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C
July 30

Immigration and Chronic Hepatitis B
July 30

Mislabeled Aspirin Increases Risk of Liver Damage
July 29

Nizoral (ketoconazole): Drug Safety Communication - Potentially Fatal Liver Injury, Risk of Drug Interactions and Adrenal Gland Problems
July 29



Follow us on Twitter


Join us on Facebook
Hcvadvocate Hcsp


 and much, much more…..




Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate
Editor-in-Chief, HBV Advocate

**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.